Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Sarcoma 85Lymphoma 58Lymphoma, Large B-Cell, Diffuse 55Lymphoma, Non-Hodgkin 34Osteosarcoma 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Hodgkin Disease 25Burkitt Lymphoma 24Testicular Neoplasms 22Neuroectodermal Tumors, Primitive, Peripheral 19Ovarian Neoplasms 18Leukemia 18Lymphoma, Follicular 17Fibrosarcoma 16Testicular Germ Cell Tumor 15Neuroblastoma 15Teratoma 14Rhabdomyosarcoma 14Lymphoma, Large-Cell, Immunoblastic 14Liposarcoma 14Lymphoma, Mantle-Cell 13Lymphoma, Large-Cell, Anaplastic 13Hemangiosarcoma 13Recurrence 12Neurofibrosarcoma 12Leiomyosarcoma 12Histiocytoma, Malignant Fibrous 12Central Nervous System Neoplasms 12Sarcoma, Synovial 11Lymphoma, B-Cell, Marginal Zone 11

Interventions

Brentuximab Vedotin 21Cyclophosphamide 20fludarabine 16Rituximab 13Lenalidomide 13Dexamethasone 12fludarabine phosphate 10Melphalan 10Busulfan 10Mycophenolic Acid 9pirtobrutinib 7dacetuzumab 7Whole-Body Irradiation 7Tacrolimus 7Bortezomib 7Doxorubicin 6Azacitidine 6ruxolitinib 5Vincristine 5Prednisone 5Imatinib Mesylate 5Bone Marrow Transplantation 5ponatinib 4pomalidomide 4Mesna 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Blood Specimen Collection 4Bendamustine Hydrochloride 4venetoclax 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hematologic Diseases × Ifosfamide × Clear all
NCT02592876 2019-05-17

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Seagen Inc.

Phase 2 Terminated
81 enrolled 15 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00529503 2015-02-25

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Seagen Inc.

Phase 2 Terminated
151 enrolled
Lymphoid

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡